Doravirine

Doravirine, sold under the brand name Pifeltro, is a non-nucleoside reverse transcriptase inhibitor medication developed by Merck & Co. for use in the treatment of HIV/AIDS.

Doravirine
Clinical data
Trade namesPifeltro
Other namesMK-1439
AHFS/Drugs.comMonograph
MedlinePlusa618048
License data
Routes of
administration		By mouth[1][2]
ATC code
Legal status
Legal status
Identifiers
  • 3-Chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydro-3-pyridinyl}oxy)benzonitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.234.454
Chemical and physical data
FormulaC17H11ClF3N5O3
Molar mass425.75 g·mol−1
3D model (JSmol)
  • Cn1c(n[nH]c1=O)Cn2ccc(c(c2=O)Oc3cc(cc(c3)Cl)C#N)C(F)(F)F
  • InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)
  • Key:ZIAOVIPSKUPPQW-UHFFFAOYSA-N

Doravirine was approved for medical use in the United States in August 2018.[7]

Doravirine is available in fixed-dose combinations with other HIV drugs such as doravirine/lamivudine/tenofovir (sold under the brand name Delstrigo).[8]

References
  1. "Pifeltro- doravirine tablet, film coated". DailyMed. 10 October 2019. Retrieved 22 September 2020.
  2. Collins S, Horn T. "The Antiretroviral Pipeline" (PDF). Pipeline Report. p. 10. Archived from the original (PDF) on 11 March 2016. Retrieved 6 December 2015.
  3. "PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION : PIFELTRO" (PDF). Pdf.hres.ca. Retrieved 5 June 2022.
  4. "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
  5. "Pifeltro 100 mg film-coated tablets - Summary of Product Characteristics (SmPC)". Medicines.org.uk. Retrieved 1 October 2020.
  6. "Pifeltro EPAR". European Medicines Agency (EMA). Retrieved 1 October 2020.
  7. "Drug Approval Package: Pifeltro (doravirine)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 22 September 2020.
  8. "Delstrigo EPAR". European Medicines Agency (EMA). 4 August 2023.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.